{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-086092","form_type":"8-K","ticker":"CLB","cik":"0001958086","company_name":"Core Laboratories Inc. /DE/","filed_at":"2024-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.271265+00:00","generated_at":"2026-05-31T17:20:57.619430+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Core Labs Q2 revenue $130.6M; GAAP EPS $0.19, ex-items $0.22; cuts net debt $15.8M; declares $0.01 dividend","bullets":["Revenue $130.6M, up slightly sequentially and YoY; operating income GAAP $16.0M, ex-items $16.4M (+10% sequentially, +5% YoY).","GAAP EPS $0.19; ex-items EPS $0.22, up 16% sequentially and 5% YoY.","Free cash flow $14.3M; net debt reduced by $15.8M during Q2 2024.","Declares Q3 2024 dividend of $0.01/share, payable Aug 26, record Aug 5, 2024.","Operating margins ex-items reached 13%, expanding over 100 bps sequentially."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-086092","json":"https://secwatch.observer/filing/0000950170-24-086092.json","markdown":"https://secwatch.observer/filing/0000950170-24-086092.md","text":"https://secwatch.observer/filing/0000950170-24-086092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024086092/0000950170-24-086092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958086/000095017024086092/clb-20240724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T17:20:57.619430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}